Clinical and angiographic characteristics at baseline
| Placebo (n=11) | Lefradafiban dose (× 3 daily) | ||||
|---|---|---|---|---|---|
| 30 mg (n=16) | 45 mg (n=16) | 60 mg (n=21) | |||
| Patient demographics | |||||
| Age (years) (mean (SD)) | 58 (7) | 65 (8) | 62 (13) | 60 (12) | |
| Male sex (n) | 8 | 14 | 11 | 14 | |
| Diabetes (n) | – | 3 | 1 | 2 | |
| Hypertension (n) | 2 | 2 | 6 | 5 | |
| Previous MI (n) | 1 | 5 | 5 | 4 | |
| Previous PTCA or CABG (n) | 1 | 3 | 3 | 3 | |
| Angiographic variables | |||||
| Segments to be treated (n) | |||||
| RCA | 3 | 2 | 3 | 6 | |
| LAD | 6 | 9 | 8 | 8 | |
| LCX | 2 | 5 | 5 | 7 | |
| Perfusion grade, TIMI flow (n) | |||||
| Grade 0 | 1 | – | 1 | – | |
| Grade 1 | 1 | – | – | 1 | |
| Grade 2 | 1 | 2 | 1 | 2 | |
| Grade 3 | 8 | 14 | 14 | 18 | |
| Lesion type by AHA/ACC (n) | |||||
| A | 1 | – | 2 | 1 | |
| B1 | 5 | 3 | 5 | 4 | |
| B2 | 5 | 10 | 6 | 9 | |
| C | – | 3 | 3 | 5 | |
| Missing | – | – | – | 2 | |
AHA/ACC, American Heart Association/American College of Cardiology; CABG, coronary artery bypass grafting; LAD, left anterior descending artery; LCX, left circumflex artery; MI, myocardial infarction; PTCA, percutaneous transluminal coronary angioplasty; RCA, right coronary artery; TIMI, thrombolysis in myocardial infarction.